Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Adv Hematol. 2011 Jun;2(3):129-39. doi: 10.1177/2040620711407675.

Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Author information

  • 1ACORN Research, LLC, Memphis, TN, USA.

Abstract

BACKGROUND:

The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear.

METHODS:

We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3-5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy.

RESULTS:

Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients.

CONCLUSIONS:

Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.

KEYWORDS:

Rituxan; follicular lymphoma; maintenance therapy; rituximab; symptoms

PMID:
23556084
[PubMed]
PMCID:
PMC3573401
Free PMC Article

Images from this publication.See all images (3)Free text

Figure 1.
Figure 2.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk